Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 16/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL390133 | 0.87 | GPR119 (0.68) | GPR119MAPTALDH1A1KDM4EMEN1 | |
| SCHEMBL5261218 | 0.78 | GPR119 (0.54) | GPR119MAPTALDH1A1 | |
| SCHEMBL388662 | 0.76 | GPR119 (0.67) | GPR119MAPTALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL6251383 | 0.76 | GPR119 (0.50) | GPR119MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL1673759 | 0.75 | GPR119 (0.62) | GPR119MAPTALDH1A1KDM4EMEN1 | |
| SCHEMBL1673858 | 0.73 | GPR119 (0.81) | GPR119MAPT | |
| SCHEMBL12733784 | 0.73 | GPR119 (0.83) | GPR119MAPT | |
| SCHEMBL389077 | 0.72 | STAT3 (0.48) | GPR119MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL5319508 | 0.72 | PTPN11 (0.50) | GPR119MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL388987 | 0.72 | GPR119 (0.71) | GPR119MAPTALDH1A1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2004157-A2 | USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AS WELL AS COMBINATION THERAPY RELATING THERETO | Arena Pharmaceuticals, Inc. (US) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007120702-A2 | USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AND COMBINATION THERAPY RELATING THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2007-10-25 | — | — | WO | disclosed |